|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GA reduces multiple sclerosis (MS) disease activity and has shown comparable efficacy with high-dose interferon-β.
|
29440323 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Three randomized trials (CAMMS223, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I, and CARE-MS II) compared two courses of alemtuzumab 12 mg with SC IFNB-1a 44 μg in patients with active relapsing-remitting MS. An extension study (CAMMS03409) provided further evaluation and as-needed alemtuzumab retreatment.
|
30289355 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The immune regulatory properties of type I IFNs have led to the approval of IFN-β for the treatment of relapsing-remitting MS.
|
31209101 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The authors aim to understand how lymphocyte populations could predict the course of multiple sclerosis (MS) in people treated with interferon-β (IFN-β).
|
30592627 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon beta (IFNβ) is an approved treatment for relapsing-remitting and secondary progressive MS.
|
30692524 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The crude rate of infections was higher in patients with MS taking interferon beta and GA than the general population (incidence rate, 8.9 [95% CI, 6.4-12.1] vs 5.2 [95% CI, 4.8-5.5] per 1000 person-years), and higher still in patients taking fingolimod (incidence rate, 14.3 [95% CI, 10.8-18.5] per 1000 person-years), natalizumab (incidence rate, 11.4 [95% CI, 8.3-15.3] per 1000 person-years), and rituximab (incidence rate, 19.7 [95% CI, 16.4-23.5] per 1000 person-years).
|
31589278 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis.
|
31331574 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Injection site reactions (ISRs) and influenza-like illness are the most common adverse effects of interferon beta therapies and can present a burden for MS patients leading to non-adherence and discontinuation of therapy.
|
31202258 |
2019 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results showed that IFN-β can reduce the proportion of Th17 cells, the levels of IL-17 and IL-23 in serum of MS.
|
31517556 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, we present new evidence supporting the importance of rare genetic variation in the inflammasome signaling pathway and its regulation via autophagy and interferon-β to the etiology of MS.
|
31235738 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess the impact of including future price reductions following LOE on the cost-effectiveness of fingolimod versus intramuscularly administered interferon beta-1a (IM IFNβ-1a) as treatments for multiple sclerosis.
|
30917079 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The oldest and most frequently used medication for MS is interferon beta, either used alone or as add-on therapy with other drugs.
|
31565644 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval of IFNβ and glatiramer acetate for the treatment of relapsing-remitting MS.
|
30315270 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease.
|
31354720 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Development of autoimmune hepatitis (AIH) has been sporadically reported in patients with multiple sclerosis (MS) either concurrently or after treatment with immunomodulatory drugs, including interferon-beta (IFN-β) and steroids.
|
30594597 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon beta (IFN-β) benefits patients with MS and reduces symptoms of the RR-MS. MxA is induced by type I interferon and predicts IFN-β response in MS patients.
|
31421628 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To analyse the association between rs7298096 and time to first relapse (TTFR) during IFNβ therapy in MS patients and to better investigate its functional role.
|
31221001 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we aimed to clarify the effects of the long-term usage of IFN-β on γδ T cell subsets in MS patients.
|
31519178 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The goal of this pilot study was to establish a digital study process that allows the collection of medication usage data and to assess medication usage among patients with MS treated with interferon beta-1b who use myBETAapp.
|
31359863 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy.
|
29521573 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two patients with MS were treated with interferon beta-1a and the third patient with azathioprine.
|
30270137 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
NfL concentrations were measured by single molecule array assay in cerebrospinal fluid (CSF) from MS patients (<i>n</i> = 235) in a 2-year randomized clinical trial (RCT) of intramuscular interferon β-1a, and in serum (<i>n</i> = 164) from the extension study.
|
31680621 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the prevalence of anti-interferon-β binding (BAb) and neutralising antibodies (NAb), and to investigate whether NAb measured by luciferase-based cell assay can predict treatment response in multiple sclerosis (MS) patients treated with interferon-β-1b (IFNβ-1b).
|
31621888 |
2019 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Long-term follow-up from the randomized trial of interferon beta-1b (IFNB-1b) permitted the assessment of different definitions of no evidence of disease activity (NEDA) for predicting long-term outcome in multiple sclerosis (MS).
|
29761737 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon beta (IFNβ) is used as a first-line treatment for multiple sclerosis (MS) and is injected intramuscularly or subcutaneously (s.c.).
|
30848986 |
2019 |